Literature DB >> 36239109

Analysis of gene expression profiles to study malaria vaccine dose efficacy and immune response modulation.

Supantha Dey1,2, Harpreet Kaur2, Mohit Mazumder2, Elia Brodsky2.   

Abstract

Malaria is a life-threatening disease, and Africa is still one of the most affected endemic regions despite years of policy to limit infection and transmission rates. Further, studies into the variable efficacy of the vaccine are needed to provide a better understanding of protective immunity. Thus, the current study is designed to delineate the effect of each dose of vaccine on the transcriptional profiles of subjects to determine its efficacy and understand the molecular mechanisms underlying the protection this vaccine provides. Here, we used gene expression profiles of pre and post-vaccination patients after various doses of RTS,S based on samples collected from the Gene Expression Omnibus datasets. Subsequently, differential gene expression analysis using edgeR revealed the significantly (false discovery rate < 0.005) 158 downregulated and 61 upregulated genes between control vs. controlled human malaria infection samples. Further, enrichment analysis of significant genes delineated the involvement of CCL8, CXCL10, CXCL11, XCR1, CSF3, IFNB1, IFNE, IL12B, IL22, IL6, IL27, etc., genes which found to be upregulated after earlier doses but downregulated after the 3rd dose in cytokine-chemokine pathways. Notably, we identified 13 cytokine genes whose expression significantly varied during three doses. Eventually, these findings give insight into the dual role of cytokine responses in malaria pathogenesis. The variations in their expression patterns after various doses of vaccination are linked to the protection as it decreases the severe inflammatory effects in malaria patients. This study will be helpful in designing a better vaccine against malaria and understanding the functions of cytokine response as well.

Entities:  

Keywords:  RNA-seq; antibody production; cytokine; gene expression; inflammation; malaria

Year:  2022        PMID: 36239109      PMCID: PMC9576474          DOI: 10.5808/gi.22049

Source DB:  PubMed          Journal:  Genomics Inform        ISSN: 1598-866X


  65 in total

1.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.

Authors:  Kent E Kester; James F Cummings; Opokua Ofori-Anyinam; Christian F Ockenhouse; Urszula Krzych; Philippe Moris; Robert Schwenk; Robin A Nielsen; Zufan Debebe; Evgeny Pinelis; Laure Juompan; Jack Williams; Megan Dowler; V Ann Stewart; Robert A Wirtz; Marie-Claude Dubois; Marc Lievens; Joe Cohen; W Ripley Ballou; D Gray Heppner
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

2.  Cytokines in the pathogenesis of malaria: levels of IL-I beta, IL-4, IL-6, TNF-alpha and IFN-gamma in plasma of healthy individuals and malaria patients in a holoendemic area.

Authors:  R N Mshana; J Boulandi; N M Mshana; J Mayombo; G Mendome
Journal:  J Clin Lab Immunol       Date:  1991-03

3.  Malaria primes the innate immune response due to interferon-gamma induced enhancement of toll-like receptor expression and function.

Authors:  Bernardo S Franklin; Peggy Parroche; Marco Antonio Ataíde; Fanny Lauw; Catherine Ropert; Rosane B de Oliveira; Dhelio Pereira; Mauro Shugiro Tada; Paulo Nogueira; Luiz Hildebrando Pereira da Silva; Harry Bjorkbacka; Douglas T Golenbock; Ricardo T Gazzinelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

4.  Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock.

Authors:  Nazima Pathan; Cheryl A Hemingway; Ash A Alizadeh; Alick C Stephens; Jennifer C Boldrick; Emmanuelle E Oragui; Colm McCabe; Steven B Welch; Adeline Whitney; Peter O'Gara; Simon Nadel; David A Relman; Sian E Harding; Michael Levin
Journal:  Lancet       Date:  2004-01-17       Impact factor: 79.321

5.  Plasma levels of the interleukin-6 cytokine family in persons with severe Plasmodium falciparum malaria.

Authors:  C Wenisch; K F Linnau; S Looaresuwan; H Rumpold
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

6.  Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response.

Authors:  Hayley A McNamara; Azza H Idris; Henry J Sutton; Rachel Vistein; Barbara J Flynn; Yeping Cai; Kevin Wiehe; Kirsten E Lyke; Deepyan Chatterjee; Natasha Kc; Sumana Chakravarty; B Kim Lee Sim; Stephen L Hoffman; Mattia Bonsignori; Robert A Seder; Ian A Cockburn
Journal:  Cell Host Microbe       Date:  2020-07-21       Impact factor: 21.023

Review 7.  Tumor necrosis factor-alpha as a myocardial depressant substance.

Authors:  M Odeh
Journal:  Int J Cardiol       Date:  1993-12-31       Impact factor: 4.164

8.  Fundamentals of vaccine immunology.

Authors:  Angela S Clem
Journal:  J Glob Infect Dis       Date:  2011-01

Review 9.  Malaria vaccines since 2000: progress, priorities, products.

Authors:  Patrick E Duffy; J Patrick Gorres
Journal:  NPJ Vaccines       Date:  2020-06-09       Impact factor: 7.344

Review 10.  Investigating the Pathogenesis of Severe Malaria: A Multidisciplinary and Cross-Geographical Approach.

Authors:  Samuel C Wassmer; Terrie E Taylor; Pradipsinh K Rathod; Saroj K Mishra; Sanjib Mohanty; Myriam Arevalo-Herrera; Manoj T Duraisingh; Joseph D Smith
Journal:  Am J Trop Med Hyg       Date:  2015-08-10       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.